Granted Patent
B2
US 12,514,855 · App. 17/925,798 · Granted Jan 6, 2026
Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
Assignee:
IRR, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Certain embodiments described herein include methods and formulations for treating or preventing symptoms and conditions associated with sepsis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
Claims (15)
1 . A method of treating a patient suffering from sepsis or septic shock, the method comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast.
2 . The method of claim 1 , wherein the treatment causes a decrease in severity in the signs or symptoms of sepsis including one or more of fever, mental confusion, diminished urine output, inadequate blood flow, nausea, vomiting, abdominal guarding, rebound pain upon removal of pressure from the abdomen, silent abdomen, pain, redness of the skin, oliguria, coagulopathy, tachycardia, rigors, myalgia, productive cough, tachypnea, sweats, dyspnea, cellulitis, borborygmus, loose stools, hemorrhagic colitis, pyelonephritis, pneumonia, obtundation, inflammation of the abdominal cavity lining, infection of the bile duct, intestinal infarction, petechiae, purpura, purpura fulminans, malaise, myalgia, arthralgia, headache, chills, rapid heart rate or rapid breathing.
3 . The method of claim 1 , wherein the treatment decreases hypotension.
4 . The method of claim 1 , wherein the treatments decreases severe sepsis.
5 . The method of claim 1 , wherein the treatment decreases septic shock.
6 . The method of claim 1 , wherein the patient is suffering from multiple organ dysfunction syndrome and/or treatment decreases mortality associated with multiple organ dysfunction syndrome.
7 . The method of claim 1 , wherein the treatment decreases coagulopathy.
8 . The method of claim 1 , wherein the combination of levocetirizine and montelukast is administered in a sequential manner.
9 . The method of claim 1 , wherein the combination of levocetirizine and montelukast is administered in a substantially simultaneous manner.
10 . The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.
11 . The method of claim 1 , wherein the levocetirizine and montelukast are administered by the same route.
12 . The method of claim 1 , wherein the levocetirizine and montelukast are administered via different routes.
13 . The method of claim 1 , wherein one or more of levocetirizine or montelukast are provided as a slow release composition.
14 . The method of claim 1 , wherein the combination further comprises other medications known for use in treating complications associated with sepsis.
15 . The method of claim 1 , wherein the combination further comprises a steroid.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 18, 2025
From: MAY, BRUCE CHANDLER
To: IRR, INC.
Reel/Frame 072044/0875 →
Continuity (2)
Provisional Application
63026983
· May 19, 2020
References Cited (197)
US 4801612A
· Wei et al.
· 1989
[cited by applicant]
US 5147637A
· Wright et al.
· 1992
[cited by applicant]
US 5211958A
· Akkerboom et al.
· 1993
[cited by applicant]
US 5540225A
· Schutt
· 1996
[cited by applicant]
US 6384038B1
· Rubin
· 2002
[cited by applicant]
US 6790849B2
· Rubin
· 2004
[cited by applicant]
US 7166640B2
· Berg
· 2007
[cited by applicant]
US 7186555B1
· Tracey et al.
· 2007
[cited by applicant]
US 7226470B2
· Kemény et al.
· 2007
[cited by applicant]
US 7291331B1
· Croft et al.
· 2007
[cited by applicant]
US 7589076B2
· Rieger et al.
· 2009
[cited by applicant]
US 9044479B2
· May
· 2015
[cited by applicant]
US 9522148B2
· May
· 2016
[cited by applicant]
US 9669025B2
· May
· 2017
[cited by applicant]
US 9669026B2
· May
· 2017
[cited by applicant]
US 9925183B2
· May
· 2018
[cited by applicant]
US 9937166B2
· May
· 2018
[cited by applicant]
US 20010025040A1
· Poppe et al.
· 2001
[cited by applicant]
US 20010033872A1
· Corson et al.
· 2001
[cited by applicant]
US 20010051624A1
· Jones
· 2001
[cited by applicant]
US 20020006961A1
· Katz et al.
· 2002
[cited by applicant]
US 20020052312A1
· Reiss et al.
· 2002
[cited by applicant]
US 20040180868A1
· Mullally
· 2004
[cited by applicant]
US 20050256131A1
· Coester
· 2005
[cited by applicant]
US 20060263350A1
· Lane
· 2006
[cited by applicant]
US 20070025987A1
· Brunetta
· 2007
[cited by applicant]
US 20070225285A1
· Hutchinson et al.
· 2007
[cited by applicant]
US 20070244128A1
· Hutchinson et al.
· 2007
[cited by applicant]
US 20080260644A1
· Cohen
· 2008
[cited by applicant]
US 20100305080A1
· O'Shea
· 2010
[cited by applicant]
US 20120040892A9
· Zimmer et al.
· 2012
[cited by applicant]
US 20120053563A1
· Du
· 2012
[cited by applicant]
US 20120190691A1
· Bouyssou et al.
· 2012
[cited by applicant]
US 20120263764A1
· Watson
· 2012
[cited by applicant]
US 20130011395A1
· Spies et al.
· 2013
[cited by applicant]
US 20130030000A1
· Chobanian et al.
· 2013
[cited by applicant]
US 20130030009A1
· Harish et al.
· 2013
[cited by applicant]
US 20150231133A1
· May
· 2015
[cited by applicant]
US 20150352102A1
· May
· 2015
[cited by applicant]
US 20170368059A1
· May
· 2017
[cited by applicant]
US 20190091218A1
· May
· 2019
[cited by applicant]
US 20190298714A1
· May
· 2019
[cited by applicant]
US 20200101067A1
· May
· 2020
[cited by applicant]
US 20200323843A1
· May
· 2020
[cited by applicant]
US 20220096465A1
· May
· 2022
[cited by applicant]
US 20230190734A1
· May
· 2023
[cited by applicant]
CN 102895661
· 2013
[cited by applicant]
CN 103505731
· 2014
[cited by applicant]
EP 1769797
· 2007
[cited by applicant]
EP 2520292
· 2012
[cited by applicant]
JP 2001511134
· 2001
[cited by applicant]
JP 2001526232
· 2001
[cited by applicant]
JP 2002511425
· 2002
[cited by applicant]
JP 2004536097
· 2004
[cited by applicant]
JP 2009520711
· 2009
[cited by applicant]
JP 2009525952
· 2009
[cited by applicant]
JP 2011500847
· 2011
[cited by applicant]
JP 2012519207
· 2012
[cited by applicant]
JP 2013528654
· 2013
[cited by applicant]
KR 1020010033485
· 2001
[cited by applicant]
RU 2442789
· 2010
[cited by applicant]
WO WO95009652
· 1995
[cited by applicant]
WO WO99032125
· 1999
[cited by applicant]
WO WO99052553
· 1999
[cited by applicant]
WO WO03002098
· 2003
[cited by applicant]
WO WO03002109
· 2003
[cited by applicant]
WO WO03101434
· 2003
[cited by applicant]
WO WO2006010283
· 2006
[cited by applicant]
WO WO2008100539
· 2008
[cited by applicant]
WO WO2008106429
· 2008
[cited by applicant]
WO WO2009022327
· 2009
[cited by applicant]
WO WO2009055729
· 2009
[cited by applicant]
WO WO2010107404
· 2010
[cited by applicant]
WO WO2011003074
· 2011
[cited by applicant]
WO WO2011041462
· 2011
[cited by applicant]
WO WO2011094209
· 2011
[cited by applicant]
WO WO2011159821
· 2011
[cited by applicant]
WO WO2012064301
· 2012
[cited by applicant]
WO WO2012064305
· 2012
[cited by applicant]
WO WO2012092594
· 2012
[cited by applicant]
WO WO2013012199
· 2013
[cited by applicant]
WO WO2013013490
· 2013
[cited by applicant]
WO WO2013148366
· 2013
[cited by applicant]
WO WO2013162135A1
· 2013
[cited by examiner]
WO WO2014090990
· 2014
[cited by applicant]
WO WO2014164281
· 2014
[cited by applicant]
WO WO2014164282
· 2014
[cited by applicant]
WO WO2014164285
· 2014
[cited by applicant]
WO WO2014164299
· 2014
[cited by applicant]
WO WO2016044095
· 2016
[cited by applicant]
WO WO2017210417
· 2017
[cited by applicant]
WO WO2021236518
· 2021
[cited by applicant]
Ciebieda. American Journal of Rhinology & Allergy, 2011, 25(1), pp. e1-e6 (Year: 2011).
[cited by examiner]
Cecconi. Lancet, 2018, 392, 75-87 (Year: 2018).
[cited by examiner]
Al-Ahmad, Mona, “Omalizumab Therapy in Three Patients with Chronic Autoimmune Urticaria”, Annals of Saudi Medicine, vol. 30, No. 6, Nov.-Dec. 2010, pp. 478-481.
[cited by applicant]
Athanasiadis et al., “Urticarial Vasculitis With a Positive Autologous Serum Skin Test: Diagnosis and Successful Therapy”, Allergy, 2006, vol. 61, pp. 1484-1485.
[cited by applicant]
Bernier et al., “Consensus Guidelines for the Management of Radiation Dermatitis and Coexisting Acne-Like Rash in Patients Receiving Radiotherapy Plus EGFR Inhibitors for the Treatment of Squamous Cell Carcinoma of the …
[cited by applicant]
Bisgaard Hans, “A Randomized Trial of Montelukast in Respiratory Syncytial Virus Postbronchiolitis”, American Journal of Respiratory and Critical Care Medicine, 2003, vol. 167, No. 3, pp. 379-383.
[cited by applicant]
Borish MD, Larry, “Allergic Rhinitis: Systemic Inflammation and Implications for Management”, The Journal of Allergy and Clinical Immunology, Dec. 1, 2003, pp. 1021-1031.
[cited by applicant]
Ciebieada, MD et al., “Montelukast with Desloratadine or Levocetirizine for the Treatment of Persistent Allergic Rhinitis”, Annals of Allergy, Asthma & Immunology, Nov. 2006, vol. 97, pp. 664-671.
[cited by applicant]
Clinical Surgery, 1999, Oct. 3, vol. 54, No. 11, Special Issue, pp. 13-15.
[cited by applicant]
Commission on Accreditation of Rehabilitation Facilities Medical Rehabilitation Standards Manual (“CARF”), Jul. 1, 2020-Jun. 30, 2021, p. 397.
[cited by applicant]
Dávila et al., “Effect of H1 Antihistamines Upon the Cardiovascular System”, Journal of Investigational Allergology and Clinical Immunology, 2006, vol. 16, No. 1, pp. 13-23.
[cited by applicant]
Deb et al., “Pathophysiologic Mechanisms of Acute Ischemic Stroke: An Overview with Emphasis on Therapeutic Significance Beyond Thrombolysis”, Pathophysiology, 2010, vol. 17, pp. 197-218.
[cited by applicant]
Eccles, Ron, “Understanding the Symptoms of the Common Cold and Influenza”, The Lancet Infectious Diseases, R(1) Nov. 2005, vol. 5, No. 11, pp. 718-725.
[cited by applicant]
El-Shanawany et al., “Clinical Immunology Review Series: An Approach to the Patient with Anaphylaxis”, British Society for Immunology, Clinical and Experimental Immunology, 2008, vol. 153, pp. 1-9.
[cited by applicant]
Elting et al., “Comparison of Serum S-100 Protein Levels Following Stroke and Traumatic Brain Injury”, Journal of the Neurological Sciences, 2000, vol. 181, pp. 104-110.
[cited by applicant]
Fedson, David, “A Practical Treatment for Patients with Ebola Virus Disease”, Journal of Infectious Diseases, Aug. 25, 2014, pp. 5.
[cited by applicant]
Fedson, David, “Treating Influenza with Statins and Other Immunomodulatory Agents”, Antiviral Research, Sep. 2013, vol. 99, No. 3, pp. 417-435.
[cited by applicant]
Fookes, Carmen, “Methylprednisolone vs Prednisone—What's the difference between them?”, Drugs.com, https://www.drugs.com/medical-answers/difference-between-methylprednisolone-prednisone-3509126/, as updated Aug. 17, 202…
[cited by applicant]
Garau et al., “Radiobiology of the Acute Radiation Syndrome”, Reports of Practical Oncology and Radiotherapy, 2011, vol. 16, pp. 123-130.
[cited by applicant]
Gil et al. “COVID-19: Drug Targets and Potential Treatments,” Journal of Medical Chemistry, 2020, 63, pp. 12359-12386.
[cited by applicant]
Glantschnig et al., “Mass Fraction Profiling Based on X-Ray Tomography and its Application to Characterizing Porous Silica Boules”, Applied Optics, Mar. 15, 1987, vol. 26, No. 6, pp. 983-989.
[cited by applicant]
Heneka et al., “Innate Immune Activation in Neurodegenerative Disease”, Nature Reviews, Immunology, Jul. 2014, vol. 14, pp. 463-477.
[cited by applicant]
Hong et al., “Urticaria and Angioedema”, Cleveland Clinic—Center for Continuing Education, Aug. 2010, pp. 11.
[cited by applicant]
Ingelsson et al., “Nationwide Cohort Study of the Leukotriene Receptor Antagonist Montelukast and Incident or Recurrent Cardiovascular Disease”, Journal of Allergy and Clinical Immunology, Mar. 2012, vol. 129, No. 3, pp…
[cited by applicant]
Jang et al., “Levoceterizine Inhibits Rhinovirus-Induced ICAM-1 and Cytokine Expression and Viral Replication in Airway Epithelial Cells”, Antiviral Research, Mar. 2009, vol. 81, No. 3, pp. 226-233.
[cited by applicant]
Jensen et al., “Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion”, Journal of Virology, Mar. 2012, vol. 86, No. 6, pp. 2900-2910.
[cited by applicant]
Jianxin et al., “Therapeutic Effectiveness Analysis of Montelukast in Therapy of Anaphylactic Purpura”, Journal of Clinical and Experimental Medicine, May 2010, vol. 9, No. 10, pp. 782-783.
[cited by applicant]
Johnson, MD, et al., “Levocetirizine and Rupatadine in Chronic Idiopathic Urticaria”, International Journal of Dermatology, 2015, vol. 54, pp. 1199-1204.
[cited by applicant]
Khoury, MD et al., “Effect of Montelukast on Bacterial Sinusitis in Allergic Mice”, Annals of Allergy, Asthma & Immunology, Sep. 2006, vol. 97, No. 3, pp. 329-335.
[cited by applicant]
Kozel et al., “Chronic Urticaria: Aetiology, Management and Current and Future Treatment Options,” Drugs, 2004, vol. 64, No. 22, pp. 2515-2536.
[cited by applicant]
Kronenberg et al., “Symptomatic Treatment of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting: Randomised, Double Blind Trial”, BMJ, 2017, vol. 359, No. J4787, pp. 10.
[cited by applicant]
Kuna et al., “Two Phase II Randomized Trials on the CR Th2 Antagonist AZD1981 in Adults with Asthma”, Drug Design, Development and Therapy, 2016, vol. 10, pp. 2759-2770.
[cited by applicant]
Kurowski et al., “Montelukast Plus Cetirizine in the Prophylactic Treatment of Seasonal Allergic Rhinitis: Influence of Clinical Symptoms and Nasal Allergic Inflammation”, Allergy, 2004, vol. 59, pp. 280-288.
[cited by applicant]
“Laboratory Tests Used in the Diagnosis and Monitoring of Rheumatoid Arthritis”, National Rheumatoid Arthritis Society (NRAS), reviewed Nov. 4, 2019 and printed Sep. 2, 2020 in 4 pages. https://www.nras.org.uk/laborator…
[cited by applicant]
Lai et al., “Montelukast Targeting the Cysteinyl Leukotriene Receptor 1 Ameliorates Aβ1-42-Induced Memory Impairment and Neuroinflammatory and Apoptotic Responses in Mice”, Neuropharmacology, Apr. 2014, vol. 79, pp. 707…
[cited by applicant]
Lishchuk-Yakymovych et al., “Positive Correlation Between Serum IL-5 and TNF-alpha Levels and Churg-Strauss Syndrome Activity in Patients Successfully Treated with Motelukast”, Journal of Allergy and Clinical Immunology…
[cited by applicant]
Luthra et al., “Mutual Antagonism between the Ebola Virus VP35 Protein and the RIG-1 Activator PACT Determines Infection Outcome”, Cell Host Microbe, Jul. 17, 2013, vol. 14, No. 1, pp. 1-23.
[cited by applicant]
“Making the Vaccine Decision: Addressing Common Concerns”, Aug. 5, 2019, CDC Evidentiary reference, https://www.cdc.gov/vaccines/parents/why-vaccinate/vaccine-decision.htm-date accessed Jan. 27, 2022, pp. 4.
[cited by applicant]
Mansi et al., “ANCA-Associated Small-Vessel Vasculitis”, American Family Physician, Apr. 15, 2002, vol. 65, No. 8, pp. 1615-1620.
[cited by applicant]
Marshall, III, M.D., William F., “COVID-19 (coronavirus) drugs: Are there any that work?” Mayo Clinic, Mayo Foundation for Medical Education and Research (MFMER). Jun. 2, 2021, 4 pages.
[cited by applicant]
Mathis et al., “Role of Leukotriene B4 Receptors in Rheumatoid Arthritis”, Autoimmunity Reviews, Nov. 2007, vol. 7, No. 1, pp. 12-17.
[cited by applicant]
Mathiesen et al., “On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2”, Molecular Pharmacology, 2006, vol. 69, No. 4, pp. 1441-1453.
[cited by applicant]
Matsen III M.D., “Rheumatoid Arthritis”, https://orthop.washington.edu/patient-care/articles/arthritis/rheumatoid-arthritis.html, printed Aug. 30, 2021 in 11 pages.
[cited by applicant]
Matteson, MD, MPH, “Current Treatment Strategies for Rheumatoid Arthritis”, Mayo Clinic Proceedings, Concise Review for Clinicians, Jan. 1, 2000, vol. 75, No. 1, pp. 69-74.
[cited by applicant]
May, B. Chandler, “A Proposed Model for the Treatment of Acute Inflammation”, Mazatlán, Mexico, LXIV Conference of the Mexican College of Clinical Immunology and Allergy, May 29, 2010, pp. 3.
[cited by applicant]
May, B. Chandler, “Contemporary Treatment of Influenza”, Santa Barbara, CA, 25th Annual Infectious Disease Conference, Dec. 18, 2009, pp. 36.
[cited by applicant]
McElroy et al., Ebola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical Outcome, Journal of Infectious Disease, Aug. 15, 2014, vol. 210, No. 4, pp. 558-566.
[cited by applicant]
McKinney et al., “The Immunopatholgy of ANCA-Associated Vasculitis”, Semin Immunopathol, 2014, vol. 36, pp. 461-478.
[cited by applicant]
Medrol®, Methylprednisolone tablets, USP, Pfizer, Revised Jul. 2018, pp. 13.
[cited by applicant]
Medzhitov, Ruslan, “Origin and Physiological Roles of Inflammation,” Nature, vol. 454, Jul. 24, 2008, pp. 428-435.
[cited by applicant]
Menon, MD, PhD et al., “Positiona Statement: Definition of Traumatic Brain Injury”, Archives of Physical Medicine and Rehabilitation, vol. 91, Nov. 2010, pp. 1637-1640.
[cited by applicant]
Min et al., “Levocetirizine Inhibits Rhinovirus-Induced Bacterial Adhesion to Nasal Epithelial Cells Through Down-Regulation of Cell Adhesion Molecules”, Annals of Allergy, Asthma and Immunology, 2012, vol. 108, pp. 44-…
[cited by applicant]
Modrykamien, MD et al., “The Acute Respiratory Distress Syndrome”, Proceedings (Baylor University Medical Center) 2015, vol. 28, No. 2, pp. 163-171.
[cited by applicant]
Moiz et al., “Formulation and Evaluation of Bilayered Tablets of Montelukast and Levocetrizine Dihydrocholoride Using Natural and Synthetic Polymers”, International Journal of Drug Delivery 3, Jan. 2011, pp. 597-618.
[cited by applicant]
Mostafa et al., “Comparative Study Evaluating Antihistamine Versus Leukotriene Receptor Antagonist as Adjuvant Therapy for Rheumatoid Arthritis”, European Journal of Clinical Pharmacology, Jul. 4, 2021, pp. 10.
[cited by applicant]
Muller, Barbara A., “Urticaria and Angioedema: A Practical Approach”, American Family Physician, 2004, vol. 69, No. 5, pp. 1123-1128.
[cited by applicant]
Murdoch et al., “Chronic Inflammation and Asthma”, Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, 2010, vol. 690, pp. 24-39.
[cited by applicant]
Namazi, M.R. “Cetirizine and Allopurinol as Novel Weapons Against Cellular Autoimmune Disorders”, International Immunopharmacology, 2004, vol. 4, pp. 349-353.
[cited by applicant]
National Institute of Health (NIH), “Therapeutic Management of Hospitalized Adults with COVID-19” COVID-19 Treatment Guidelines, Jul. 8, 2021, 10 pages.
[cited by applicant]
Nederkoorn et al., “Preventive Antibiotics in Stroke Study: Rationale and Protocol for a Randomised Trial”, International Journal of Stroke, Apr. 2011, vol. 6, pp. 159-163.
[cited by applicant]
Nonaka et al., “Prolonged Activation of NF-κB Following Traumatic Brain Injury in Rats”, Journal of Neurotrauma, Nov. 1999, vol. 16, No. 11, pp. 1023-1034.
[cited by applicant]
Parker, MD et al., “A 48 Year Old Man with Recurrent Sinusitis, 1 Year Later”, JAMA, Clinical Crossroads Update, Jan. 24/31, 2001, vol. 285, No. 4, p. 462.
[cited by applicant]
Pellicane, MD, et al., “Calorie and Protein Intake in Acute Rehabilitation Inpatients with Traumatic Spinal Cord Injury Versus Other Diagnoses”, Topics in Spinal Cord Injury Rehabilitation, 2013, vol. 19, No. 3, pp. 229…
[cited by applicant]
Permin et al., “Possible Role of Histamine in Rheumatoid Arthritis”, Allergy, 1981, vol. 36, pp. 435-436.
[cited by applicant]
Peroni et al., “Combined Cetirizine-Montelukast Preventative Treatment for Food-Dependent Exercise-Induced Anaphylaxis”, Annals of Allery, Asthma, & Immunology, Mar. 2010, vol. 104, pp. 272-273.
[cited by applicant]
Popov et al., “A Comparison of Levocetirizine and Desloratadine in the Histamine-Induced Wheal and Flare Response in Human Skin in Vivo”, Inflammatory Research, Jun. 2006, vol. 55, No. 6, pp. 241-244.
[cited by applicant]
“Prostaglandin DP2 receptor”, Wikipedia, <https://en.wikipedia.org/wiki/Prostaglandin_DP2_receptor>, Aug. 25, 2017, pp. 9.
[cited by applicant]
Pushparaj et al., “The Cytokine Interleukin-33 Mediates Anaphylactic Shock”, with Retraction and Correction, Proceeding of the National Academy of Sciences of the United States of America (PNAS), Jun. 16, 2009, vol. 106…
[cited by applicant]
Quercia et al., “Adalimumab Desensitization after Anaphylactic Reaction”, Allergy, 2010, vol. 65, No. 92, pp. 242-243.
[cited by applicant]
Radlińska et al., “Montelukast—Recent Advances in Determining the Role of Leukotriene Inhibitor in Allergic Diseases”, International Review of Allergology and Clinical Immunology, Jan. 2011, vol. 17:1-2, pp. 35-39.
[cited by applicant]
Rosen et al., “New Approaches to Radiation Protection,” Frontiers in Oncology, Jan. 20, 2015, vol. 4, No. 381, pp. 1-15.
[cited by applicant]
Roumestan et al., “Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms”, Clinical and Experimental Allergy, Jun. 2008,…
[cited by applicant]
Schad et al., “Effect of Montelukast on Pro-inflammatory Cytokine Production During Naturally 174 Acquired Viral Upper Respiratory Infections (vURIs) in Adults”, Journal of Allergy and Clinical Immunology, Elsevier, Ams…
[cited by applicant]
Singh-Franco et al., “Levocetirizine for the Treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria in Adults and Children”, Clinical Therapeutics, vol. 31, No. 8, Aug. 2009, pp. 1664-1687.
[cited by applicant]
Spiropoulou et al., “RIG-I Activation Inhibits ebolavirus Replication”, Virology, 2009, 392, pp. 11-15.
[cited by applicant]
Taber's® Cyclopedic Medical Dictionary, “Trauma”, 18th Edition, 1997, pp. 1988-1989.
[cited by applicant]
Tang, Angela, “A Practical Guide to Anaphylaxis”, American Family Physician, Oct. 1, 2013, vol. 68, No. 7, pp. 1325-1333.
[cited by applicant]
Tillement et al., “Compared Pharmacological Characteristics in Humans of Racemic Cetirizine and Levocetirizine, Two Histamine H1-Receptor Antagonists”, Biochemical Pharmacology, 2003, pp. 1123-1126.
[cited by applicant]
Tillie-Leblond et al., “Relation Between Inflammation and Symptoms in Asthma”, Allergy, vol. 64, No. 3, Mar. 1, 2009, pp. 354-367.
[cited by applicant]
Vasculitis Foundation, http://vasculitisfoundation.org/education/forms/urticarial-vasculitis/, 2017.
[cited by applicant]
Williams et al., “Animal Models and Medical Countermeasures Development for Radiation-Induced Lung Damage: Report from an NIAID Workshop”, Radiation Research, 2012, vol. 177, No. 5, pp. 25-39.
[cited by applicant]
Wilson, D.C., “Effect of an Anti-Histamine in Rheumatoid Arthritis”, Hospital for Rheumatic Diseases, Strathpeffer, Nov. 20, 1952, pp. 38-39.
[cited by applicant]
Wong et al., “Characterization of Host Immune Responses in Ebola Virus Infections”, Expert Review of Clinical Immunology, 2014, vol. 10, No. 6, pp. 781-790.
[cited by applicant]
Wu et al., “Add-On Therapy with Montelukast in the Treatment of Henoch-Schönlein Purpura”, Pediatrics International, 2014, vol. 56, pp. 315-322.
[cited by applicant]
Yu et al., “Montelukast, a Cysteinyl Leukotriene Receptor-1 Antagonist, Dose- and Time-Dependently Protects Against Focal Cerebral Ischemia in Mice”, Pharmacology, Jan. 2005, vol. 73, No. 1, pp. 31-40.
[cited by applicant]
Zana, Larry, “Qrono—Reformulating known, approved drugs”, as printed Jun. 23, 2014, pp. 12.
[cited by applicant]
Zappalà et al., “Traumatic brain injury and the frontal lobes: What can we gain with diffusion tensor imaging?” Cortex, 2011, pp. 1-10.
[cited by applicant]
Zhang et al., “Contrastive Observation of Loratadine and Cetirizine in Therapy of Anaphylactic Purpura”, Chinese Remedies & Clinics, May 2008, pp. 65-66.
[cited by applicant]
Khodir et al., “Montelukast Reduces Sepsis-Induced Lung and Renal Injury in Rats”, Canadian Journal of Physiology and Pharmacology, Oct. 2014, vol. 92, No. 10, pp. 839-847.
[cited by applicant]
Sener et al., “Amelioration of Sepsis-Induced Hepatic and Ileal Injury in Rats by the Leukotriene Receptor Blocker Montelukast”, Prostaglandins Leukot Essent Fatty Acids, Dec. 2005, vol. 73, No. 6, pp. 453-462.
[cited by applicant]
Extended European Search Report received in European Patent Application No. 21809416.7 dated Mar. 5, 2024 in 10 pages.
[cited by applicant]